---
title: "Pregnancy Outcomes After Prenatal Prescription Stimulant Use in Individuals with Opioid Use Disord"
id: "medrxiv-4-maternal-and-neonatal-outcomes-associated-with-prenatal-prescription-stimulant"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-4-maternal-and-neonatal-outcomes-associated-with-prenatal-prescription-stimulant"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1?rss=1"
published_at: "2026-11-15T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pregnancy Outcomes After Prenatal Prescription Stimulant Use in Individuals with Opioid Use Disord
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-4-maternal-and-neonatal-outcomes-associated-with-prenatal-prescription-stimulant
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1?rss=1)
- **Published At:** 2026-11-15T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators performed a retrospective cohort study of Tennessee Medicaid–insured pregnancies with **opioid use disorder** from 2010–2021. The cohort totaled 12,327 pregnancies; 380 (3.1%) had prescription amphetamine- or methylphenidate-class **stimulant** exposure during pregnancy. - The primary maternal outcome measured was postpartum overdose from delivery through one year; secondary maternal outcomes included death, severe maternal morbidity, and cardiovascular complications within six weeks postpartum. - The primary neonatal outcome was **preterm birth**; neonatal secondary outcomes included low birth weight, **NICU** admission, neonatal opioid withdrawal syndrome (NOWS), and death. - Investigators used overlap weighting to calculate adjusted odds ratios and predicted probabilities; they evaluated effect modification by **buprenorphine** treatment and performed subgroup analyses for ADHD and stimulant use disorder. - Adjusted analyses found no association between stimulant exposure and postpartum overdose (aOR 1.13; 95% CI, 0.61–2.08), preterm birth (aOR 1.04; 95% CI, 0.74–1.46), cardiovascular complications, severe maternal morbidity, low birth weight, or NOWS. - Stimulant exposure was associated with higher odds of **NICU** admission (aOR 1.58; 95% CI, 1.17–2.14) while maternal and infant deaths remained rare in the cohort. - Exploratory findings included an interaction: overdose odds were higher when stimulants and **buprenorphine** were both prescribed (P for interaction = .03). The ADHD subgroup showed an elevated cardiovascular composite (aOR 2.33; 95% CI, 1.13–4.82). - Authors concluded that these OUD-specific estimates do not support routine discontinuation of clinically indicated stimulant therapy in pregnancy, and they suggested the increased **NICU** admission likely reflects intensified surveillance rather than direct neonatal harm. - Data availability was restricted; the study is a preprint and has not undergone peer review. Replication of the two exploratory signals is required before changing practice.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=BGmetS..RF_2LyfkFrSQsvuI0ZtMtsXaCjqe4Nmyevc-1794807104.1664164-1.2.1.1-dRfP_Mz5AQEKW82jrU8_fXC_pekh5bQrIuZSiIGUUDzIgUuEjskn3VYIKnWcxjx6) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Maternal and Neonatal Outcomes Associated with Prenatal Prescription Stimulant Treatment Among Pregnant Individuals with Opioid Use Disorder [ View ORCID Profile](http://orcid.org/0000-0002-1081-1670)Thomas Reese, Ashley A Leech, Julia C Phillippi, Stephen Patrick, Elizabeth McNeer, Sarah Loch, Jessica Young, Amanda von Horn, Mauli V Shah, Andrew D Wiese doi: https://doi.org/10.64898/2026.11.12.26367944 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Thomas Reese 1 Vanderbilt University Medical Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2BReese%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Reese%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThomas%2BReese%2B) * [ORCID record for Thomas Reese](http://orcid.org/0000-0002-1081-1670 "Open in new tab") * For correspondence: thomas.reese@vumc.org Ashley A Leech 1 Vanderbilt University Medical Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ashley%2BA%2BLeech%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Leech%20AA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAshley%2BA%2BLeech%2B) Julia C Phillippi 2 Vanderbilt University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julia%2BC%2BPhillippi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Phillippi%20JC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJulia%2BC%2BPhillippi%2B) Stephen Patrick 3 Emory University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Stephen%2BPatrick%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Patrick%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AStephen%2BPatrick%2B) Elizabeth McNeer 1 Vanderbilt University Medical Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elizabeth%2BMcNeer%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=McNeer%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElizabeth%2BMcNeer%2B) Sarah Loch 3 Emory University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sarah%2BLoch%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Loch%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASarah%2BLoch%2B) Jessica Young 1 Vanderbilt University Medical Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jessica%2BYoung%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Young%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJessica%2BYoung%2B) Amanda von Horn 1 Vanderbilt University Medical Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amanda%2Bvon%2BHorn%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=von%20Horn%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmanda%2Bvon%2BHorn%2B) Mauli V Shah 1 Vanderbilt University Medical Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mauli%2BV%2BShah%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Shah%20MV&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMauli%2BV%2BShah%2B) Andrew D Wiese 1 Vanderbilt University Medical Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andrew%2BD%2BWiese%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wiese%20AD&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAndrew%2BD%2BWiese%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1345360/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1345360/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1345360/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1345360/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1345360/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1345360/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract ABSTRACT Introduction: Clinicians and Medicaid programs must decide whether to continue prescription stimulants in pregnancies complicated by opioid use disorder (OUD), yet no safety evidence exists for this population and stimulant coverage is frequently restricted. We evaluated maternal and neonatal outcomes associated with prescription stimulant treatment during pregnancy among individuals with OUD, including those with co-occurring stimulant use disorder (StUD) and attention-deficit/hyperactivity disorder (ADHD). Methods: We conducted a retrospective cohort study of Medicaid–insured pregnant individuals in Tennessee (2010–2021) with OUD. Our exposure of interest was any prescription amphetamine– or methylphenidate–class stimulant overlapping pregnancy. The primary maternal outcome was overdose from delivery through 1 year postpartum; secondary outcomes included death, severe maternal morbidity and cardiovascular complications in the first 6 weeks postpartum. The primary neonatal outcome was preterm birth; secondary outcomes included low birth weight, NICU admission, neonatal opioid withdrawal syndrome (NOWS), and death. We used overlap weighting to estimate adjusted odds ratios (aORs) and predicted probabilities and evaluated effect modification by buprenorphine. Results: Among 12,327 pregnancies with OUD, 380 (3.1%) received prescription stimulants during pregnancy; stimulant treated individuals were slightly older and more likely to have mental health comorbidities. In adjusted analyses, stimulant treatment was not associated with postpartum overdose (aOR, 1.13; 95% CI, 0.61–2.08), preterm birth (aOR, 1.04; 95% CI, 0.74–1.46), cardiovascular complications, severe maternal morbidity, low birth weight, or NOWS. Odds of NICU admission were higher among stimulant exposed infants (aOR, 1.58; 95% CI, 1.17–2.14). Maternal and infant deaths were rare. In exploratory analyses, overdose odds were elevated among pregnancies receiving both stimulants and buprenorphine (P for interaction = .03) and the cardiovascular composite was elevated within the ADHD subgroup (aOR, 2.33; 95% CI, 1.13–4.82). Conclusions: These first OUD-specific estimates do not support routine discontinuation of clinically indicated stimulant therapy in pregnancy. Higher NICU admission among stimulant-exposed infants, unaccompanied by differences in preterm birth, low birth weight, gestational age, or NOWS, is more consistent with intensified surveillance than with neonatal harm. Two exploratory signals require replication before they can inform practice. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Vanderbilt University Medical Center and Tennessee Department of Health institutional review boards and the Division of TennCare gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Data are not available. ## Funder Information Declared Eunice Kennedy Shriver National Institute of Child Health and Human Development, https://ror.org/04byxyr05, 1P50HD106446 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.12.26367994v1 "FlahyRecovery is an AI & gene expression based immune profiling biomarker for decision support in precision oncology")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.12.26367978v1 "Sleep Irregularity and Risk of Incident Hypertension in the UK Biobank") Posted November 15, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/15/2026.11.12.26367944.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.12.26367944v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/15/2026.11.12.26367944.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Maternal and Neonatal Outcomes Associated with Prenatal Prescription Stimulant Treatment Among Pregnant Individuals with Opioid Use Disorder Thomas Reese, Ashley A Leech, Julia C Phillippi, Stephen Patrick, Elizabeth McNeer, Sarah Loch, Jessica Young, Amanda von Horn, Mauli V Shah, Andrew D Wiese medRxiv 2026.11.12.26367944; doi: https://doi.org/10.64898/2026.11.12.26367944 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.12.26367944v1%26text%3DMaternal%2520and%2520Neonatal%2520Outcomes%2520Associated%2520with%2520Prenatal%2520Prescription%2520Stimulant%2520Treatment%2520Among%2520Pregnant%2520Individuals%2520with%2520Opioid%2520Use%2520Disorder "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.12.26367944v1%26t%3DMaternal%2520and%2520Neonatal%2520Outcomes%2520Associated%2520with%2520Prenatal%2520Prescription%2520Stimulant%2520Treatment%2520Among%2520Pregnant%2520Individuals%2520with%2520Opioid%2520Use%2520Disorder "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.12.26367944v1%26title%3DMaternal%2520and%2520Neonatal%2520Outcomes%2520Associated%2520with%2520Prenatal%2520Prescription%2520Stimulant%2520Treatment%2520Among%2520Pregnant%2520Individuals%2520with%2520Opioid%2520Use%2520Disorder%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.12.26367944v1%26title%3DMaternal%2520and%2520Neonatal%2520Outcomes%2520Associated%2520with%2520Prenatal%2520Prescription%2520Stimulant%2520Treatment%2520Among%2520Pregnant%2520Individuals%2520with%2520Opioid%2520Use%2520Disorder "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.12.26367944) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.12.26367944v1&count=horizontal&via=&text=Maternal%20and%20Neonatal%20Outcomes%20Associated%20with%20Prenatal%20Prescription%20Stimulant%20Treatment%20Among%20Pregnant%20Individuals%20with%20Opioid%20Use%20Disorder&counturl=www.medrxiv.org/content/10.64898/2026.11.12.26367944v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (639) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (922) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (354) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5035) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (430) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (680) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1701) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16308) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1243) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7308) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (757) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1096) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5323) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1476) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1841) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1385) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16515) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1205) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (701) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (157) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (755) * [Neurology](https://www.medrxiv.org/collection/neurology) (7632) * [Nursing](https://www.medrxiv.org/collection/nursing) (380) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1136) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1298) * [Occupational and Environ
## Related Clinical Research

- [High blood lead levels in pregnant women in Amran, Yemen linked to prior spontaneous abortion](https://medichelpline.com/clinical-feed/plos-one-19-elevated-blood-lead-levels-among-pregnant-women-in-amran-yemen-socio.md)
- [Long-term complication profiles after transsphenoidal vs transcranial resection of adult craniopha](https://medichelpline.com/clinical-feed/plos-one-9-long-term-complication-profiles-following-transsphenoidal-and-transcranial.md)
- [Traffic‑Light Lifestyle Program in an Integrative Clinic: Real‑World Patient‑Reported Outcomes](https://medichelpline.com/clinical-feed/medrxiv-15-real-world-outcomes-of-a-traffic-light-approach-to-lifestyle-modification-in.md)
- [CHW experiences using the ComBaCaL CHT for hypertension and diabetes care in rural Lesotho](https://medichelpline.com/clinical-feed/medrxiv-8-community-health-workers-experiences-with-a-digital-clinical-decision-support.md)
- [Postpartum Glycemic Control and Links to MMP-9, ET-1, Hypertension, and Dyslipidemia in Women with](https://medichelpline.com/clinical-feed/pubmed-43061853.md) (DOI: 10.1080/10641955.2026.2753956)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.